Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atara Biotherapeutics Inc.

www.atarabio.com

Latest From Atara Biotherapeutics Inc.

Opening The Door For Cell Therapy In Solid Tumors

The next frontier for cell therapy is solid tumors – and of the many attempts to move from liquid to solid tumors, tumor infiltrating lymphocytes and other CAR-T constructs are some of the most promising. 

Clinical Trials ImmunoOncology

Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label

Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.

Financing Business Strategies

Vical Faced With Failure of Another Vaccine Trial

Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.

Research & Development Infectious Diseases

Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Atara Biotherapeutics Inc.
  • Senior Management
  • Pascal Touchon, MD, Pres. & CEO
    Utpal Koppikar, SVP, CFO
    Christopher Haqq, MD, PhD, EVP, R&D & CSO
  • Contact Info
  • Atara Biotherapeutics Inc.
    Phone: (650) 278-8930
    611 Gateway Blvd.
    Ste. 900
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register